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Objective:Although carotid endarterectomy (CEA), the gold standard in stroke prevention, has been performed in the late
stage after the insult, its optimal timing remains unclear. Using biomarkers in plaque and plasma, we evaluated oxidative
stress and plaque vulnerability between early and late CEA in symptomatic patients.
Methods:We compared symptomatic stroke patients who underwent early CEA within 4 weeks of the last insult (group A;
n  15) with those who received CEA in the late stage beyond 4 weeks from the last symptom (group B; n  57). They
were divided into vulnerable (group Av, n  13; group Bv, n  33) and stable (group As, n  2; group Bs, n  24)
subgroups according to the pathologic findings on their plaques. We studied the relationships among their primary
symptoms, clinical findings, oxidized low-density lipoprotein levels, and gelatinase A (matrix metalloproteinase [MMP]-
9) activity in their plaques and plasma.
Results:Group A had a variety of symptoms; there was no difference in the outcome of CEA between groups A and B. The
plaque and plasma oxidized low-density lipoprotein levels were higher in group A than in group B (P < .05). The
incidence of pathologically vulnerable plaque was higher in group A than in group B. Plaque oxidized low-density
lipoprotein levels and MMP-9 activity were similar in group Av and group Bv and were higher in those groups than in
group As and Bs.
Conclusions: We first demonstrated that vulnerable plaques in patients subjected to early CEA manifested a remarkable
increase in oxidized low-density lipoprotein and MMP-9 activation. Our findings suggest that early CEA may be
beneficial in the aspect of oxidative stress. ( J Vasc Surg 2007;46:870-5.)Several studies have shown the efficacy of carotid end-
arterectomy (CEA) in patients with symptomatic carotid
artery stenosis.1,2 The optimal timing of CEA after stroke
or transient ischemic attack (TIA) remains controversial.
Although Blaisdell et al3 recommended a delay of 6 to 8
weeks between the insult and operation to reduce the risk
of conversion of a bland to a hemorrhagic infarct, more
recent studies suggested that such a delay is not necessary.
Rothwell et al4 indicated that the timing of operation is
important and that the procedure should be performed
within 2 weeks of the patient’s last symptoms. Particularly
among women with symptomatic stenosis, the benefit de-
rived from CEA was apparent only in those randomized
within 2 weeks of their last symptom; it decreased rapidly
during the first few weeks.5 Other papers also suggested
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870that CEA might be performed within 2 to 4 weeks of TIA
or stroke onset.6,7
Oxidized low-density lipoprotein plays a crucial role in
the development of atherosclerosis.8,9 In our earlier stud-
ies10,11 we classified plaques from patients who under-
went CEA in the late phase (beyond 4 weeks from their
last symptoms) into macrophage-rich (vulnerable) and
macrophage-poor (stable) plaques and demonstrated that
patients with the vulnerable plaques manifested high plaque
and plasma oxidized LDL levels.11 We also demonstrated12
an oxidant/antioxidant imbalance in these patients. To-
gether, our results suggested that patients with vulnerable
plaque were under severe oxidative stress.
In our recent series of patients, we performed CEA
within 4 weeks of the last insult. We compared the primary
symptoms, clinical findings, and biomarker levels in the
plaques and plasma with those in patients who underwent
CEA beyond 4 weeks from their last symptoms. We also
assessed whether early CEA benefits symptomatic patients
in the aspect of oxidative stress and plaque vulnerability.
SUBJECTS AND METHODS
A total of 112 patients underwent CEA at the University
of Tokushima Hospital between February 2001 and Decem-
ber 2005.Among those patients, 72 consecutive symptomatic
patients were included in this study. Prior informed consent
was obtained from all study participants. Fifteen patients
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range, 54-74 years) underwent CEA in the early stage, and 57
(group B, 47 men and 10 women; average age, 69.2 years;
range, 38-82 years) were treated in the late phase. CEA was
considered as “early” if performed within 4 weeks of the last
symptoms and “late” if performed after aminimumof 4weeks
following the most recent symptom.
All CEAs were performed according to the criteria
established by the North American Symptomatic Carotid
Endarterectomy Trial (NASCET).2 Magnetic resonance
imaging and cerebral angiography were performed in all
patients. Although patients admitted within 4 weeks of the
last attack underwent CEA as soon as possible, the choice of
the timing of operation was made by the individual sur-
geons from the patient’s state of ischemic heart disease and
the results of magnetic resonance imaging findings with or
without large cerebral infarction and hemorrhagic transfor-
mation. There is some pre-existing institutional bias toward
performing CEA in a late fashion in patients who have
experienced large preoperative cerebral infarction as a result
of the early reports.3 The interval from the last symptom to
CEA in group A patients was as follows: 1 to 2 weeks, 5
(33.3%) of 15; and 3 to 4weeks, 10 (66.7%) of 15. In group
B patients it was as follows: 5 to 6 weeks, 8 (14.0%) of 57;
7 to 8 weeks, 13 (22.8%) of 57; 9 to 16 weeks, 25 (43.9%)
of 57; and 17 to 52 weeks, 11 (19.3%) of 57 (Fig 1).
The Table provides a summary of the clinical data of
group A and B patients. In group A, the severity of neuro-
logic symptoms at admission was as follows: seven (46.7%)
had no neurologic deficit (TIA), seven (46.7%) had a
nondisabling stroke (National Institutes of Health Stroke
Scale [NIHSS] 0-4), and one (6.6%) had a moderately
disabling stroke (NIHSS). In group B, 27 (47.4%) had no
neurologic deficit (TIA), 27 (47.4%) had a nondisabling
stroke (NIHSS 0-4), and 3 (5.2%) had a moderately dis-
abling stroke (NIHSS). There was no significant difference
in the demographics between groups.
In group A, fewer patients had diabetes mellitus than in
group B, and there was no significant difference in the ratio
of other risk factors: hypertension, 7 (46.7%) in group A vs
41 (71.9%) in group B; hyperlipidemia, 5 (30%) vs 23
(40.4%); diabetes mellitus, 0 vs 22 (38.6%); ischemic heart
disease, 1 (6.7%) vs 16 (28.1%); and smoking, 9 (60%) vs 39
(68.9%), respectively.
Carotid plaque and plasma samples. Carotid
plaques obtained at CEA were immediately immersed in
phosphate-buffered saline (pH 7.4) containing proteinase
inhibitors and ethylenediaminetetra-acetic acid-2Na. For
immunohistochemical studies, we cut out and fixed the
most severe portion of the plaque, which was the most
severe stenotic portion at the cross-sectional distance and
had the greatest lipid core at the common carotid artery
bifurcation or just distal to the bifurcation in almost all
cases. The remaining portion was weighed and homogenized
in a 5 volume of phosphate-buffered saline of each plaque
weight; the other was stored at 80oC until use. Venous
blood was drawn into tubes containing ethylenediaminetetra-
acetic acid-2Na and separated by centrifugation at 4oC.Isolation of LDL. LDL isolation was by potassium
bromide stepwise density-gradient ultracentrifugation;
standard oxidized LDL was prepared by incubating LDL
with 5 mol/L CuSO4 (37
oC for 3 hours). Antioxidized
LDL monoclonal antibodies (mAbs) were prepared as de-
scribed previously.13,14
Determination of plasma oxidized LDL levels. The
plasma oxidized LDL level was measured with a commonly
accepted procedure11,15-18 by using a sandwich enzyme-
linked immunosorbent assay with mAbs against oxidized
phosphatidylcholine (FOH1a/DLH3; DLH3) and apoli-
poprotein B immunoglobulin G antibody (Boehringer-Man-
heim, Ridgefield, Conn).13,14 The complex was detected by
phosphatase-conjugated donkey anti-sheep immunoglobulin
G antibody (Chemicon, Temecula, Calif) and visualized by
incubation with substrate solution containing 1 mg/mL of
disodium p-nitrophenyl-phosphate hexahydrate (Wako,
Osaka, Japan). Absorbance was measured at 405 nm. Simul-
taneously, a parallel set of enzyme-linked immunosorbent
assayswas run to determine the amount of apolipoproteinB in
the same lipoprotein fractions by using anti-apolipoprotein B
mAb (OEM, TomsRiver, NJ). The oxidized LDL levels were
expressed as the amount of oxidized LDL per microgram of
apolipoprotein B protein.
Zymography. Gelatinase A (matrix metalloproteinase
[MMP]-2; 72-kDa type IV collagenase) and B (MMP-9;
92-kDa type IV collagenase), members of theMMP family,
are able to degrade components of the extracellular matrix.
Gelatinase activity in the plaques was assessed zymographi-
cally. Thawed, homogenized carotid plaques were soni-
cated and centrifuged. The supernatant was used after the
protein level was determined with the BCA kit (Pierce,
Rockford, Ill). Each plaque sample was adjusted to a 10-g
protein level, and 0.5 mmol/L calcium chloride and 1
mol/L zinc chloride were added to remove the effect of
ethylenediaminetetra-acetic acid. The plaque sample was
prepared for analysis by dilution in sample buffer consisting
of 126 mmol/L Tris (pH 6.8), 4% sodium dodecyl sulfate,
20% glycerol, and 0.03% bromophenol blue and loaded
onto gels. To standardize and normalize the gelatinase
activity, we used gelatinase zymography standards for hu-
Fig 1. Distribution of the timing of carotid endarterectomy after
the last neurologic symptoms in groups A and B.man MMP-2 and MMP-9 (Chemicon) with a molecular
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phoresis. After electrophoresis at 125 V, the gels were
incubated in renaturing buffer for 60 minutes at room
temperature and then for 24 hours at 37oC in a developing
buffer containing 50 mmol/L Tris (pH 7.5), 200 mmol/L
NaCl, 4 mmol/L CaCl2, and 0.02% Brij 35. The gels were
stained with 0.5% Coomassie blue G-250 in 30% metha-
nol/10% acetic acid and then destained in 30% methanol/
10% acetic acid. Gelatinase activity appears as unstained
bands in the gel. Digestion was quantified on a gel scanner
featuring an interface to the computer. The gels were
analyzed with the aid of Image J software (National Insti-
tutes of Health), and the relative value was calculated
against the standard. These experiments were individually
repeated three times in each plaque sample.
Immunohistochemical analysis. Serial paraffin sec-
tions were immunohistochemically stained by using mouse
mAb against macrophages (HAM-56; DAKO, Kyoto, Ja-
pan), DLH3, and rabbit polyclonal antibody against
MMP-9 (Chemicon). For signal detection we used the
Histofine simple stain MAX-PO (Nichirei, Tokyo, Japan)
followed by diaminobentidine or a fluorescence probe
(Alexa Fluor 488 and 594; Molecular Probes, Eugene,
Ore) as a secondary antibody and observed by using a
fluorescent microscope (IX71-22 TFL; Olympus, Tokyo,
Japan). Negative control slides were prepared by omitting
the primary antibodies. To determine macrophage infiltra-
tion and the size of the lipid core, we used an image-analysis
program (Mac Scope, Mitani Co, Osaka, Japan). Carotid
plaques were classified as vulnerable or stable according to
the level of macrophage infiltration (5% of the total
area)10-12,19 by researchers (K.T.K., K.Y., and T.T.) who
were not cognizant of either the plaque oxidized LDL
levels or the patients’ clinical data. Groups A (n  15) and
B (n  57), operated on in the early or late phase, respec-
tively, were subdivided according to whether the plaque
was judged to be vulnerable (group v) or stable (group s).
Statistics. Sequentially obtained data, expressed as the
mean SD,were analyzedwith theMann-WhitneyU test for
two-group comparisons andwith analysis of variance followed
by the Scheffé test for multigroup comparisons. Correlations
were examined by the Spearman rank correlation test, the 2
test, and the Fisher test. Statistical analyses were performed
with Stat View 5 (SAS Institute, Tokyo, Japan). Differences
were considered statistically significant at P .05.
RESULTS
Although two group A patients (13.3%) experienced
transient post-CEA neurologic deterioration, recovery was
immediate (within 24 hours after operation), and the mor-
tality and morbidity rate was 0%. One of the 57 group B
patients experienced hyperperfusion syndrome, with dete-
rioration in his cognitive status; however, magnetic reso-
nance imaging at discharge did not show a new lesion.
Another patient experienced TIA. The mortality and mor-
bidity rate in group B was therefore 3.5%.
We found no significant correlation between plasma
lipid parameters and oxidized LDL levels in plasma. More-over, the presence of risk factors seemed to have no effect
on plasma and plaque oxidized LDL levels (data not
shown).
The plaque and plasma oxidized LDL levels in group A
(27.3  18.5 ng/g and 0.27  0.08 ng/g apolipopro-
tein B, respectively) were significantly higher than in group
B (13.5  12.8 ng/g and 0.21  0.08 ng/g apoli-
poprotein B, respectively; P  .05; Fig 2). In group A, 13
plaques (86.7%) were vulnerable, and 2 (13.3%) were sta-
ble. In group B, 33 (57.8%) were vulnerable, and 24
(42.2%) were stable. This ratio of vulnerable to stable
plaques was significantly different between groups (P 
.05; Fig 3, A).
In our study population of 72 patients, the plaque
oxidized LDL level in vulnerable plaques (n  46) was
significantly higher than that in stable plaques (n  26).
However, when we compared group Av and group Bv, we
found that the plaque oxidized LDL level was not signifi-
cantly different (Fig 3, B). Figure 3, C to E, presents our
plaque zymography results. Although MMP-2 was present
in all subgroups, only vulnerable plaques were positive for
MMP-9 (Fig 3, E). There was no significant difference with
respect to the activity ofMMP-9 between groups Av and Bv
(Fig 3, D), although it was greater in the vulnerable than
Fig 2. Plaques and plasma oxidized low-density lipoprotein
(OxLDL) levels in group A and B patients. *P  .05.
Table. Summary of characteristics of patients in groups A
and B
Variable
Group A
(n  15)
Group B
(n  57)
Age (y) 65.4  7.0
(54-74)
69.2  7.4
(38-82)
Men:women 14:1 47:10
Degree of ICA stenosis (%) 81.5  14.6
(50-95)
83.8  12.7
(60-99)
Clinical symptom
TIA 7 (46.7%) 27 (47.4%)
Nondisabling stroke 7 (46.7%) 27 (47.4%)
Moderately disabling
stroke
1 (6.6%) 3 (5.2%)
ICA, Internal carotid artery; TIA, transient ischemic attack.
Data are mean  SD (range), ratios, or percentages.the stable plaques (Fig 3, D).
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were significantly different from stable plaques with respect to
the lipid-rich core, rupture, fibrous cap thinning, and in-
traplaque hemorrhage. Immunohistochemically, oxidized
LDL and MMP-9 antigen were colocalized (Fig 4). More-
over, MMP-9 and oxidized LDL were strongly positive in
vulnerable compared with stable plaque (Figs 4 and 5). In the
vulnerable plaque of group Av, the histopathologic changes
were adjacent to the vascular lumen (Fig 4).
DISCUSSION
This is the first demonstration that the incidence of
vulnerable plaques was significantly higher in patients who
underwent CEA in the early stage ( group A; 86.7%) than in
those who were treated in the late stage (group B; 57.8%).
Moreover, the plaque and plasma oxidized LDL levels were
significantly higher in group A than group B.
Early CEA risks transforming a bland ischemic infarct into
a hemorrhagic infarct,3 whereas delaying CEA risks occlusion
of the stenotic carotid artery, TIA, or stroke recurrence. Blaser
et al20 reported that 10.5% of patients with recent stroke were
at risk of developing subsequent cerebral ischemia during a
Fig 3. A, Ratio of vulnerable plaques in each group
low-density lipoprotein (OxLDL) level in each group. **P
in groups A and B. D, Plaque MMP-9 activity in each g
individual three experiments were repeated in each plaqu
M, maker (positive control).median follow-up period of 19 days. The reported benefits ofearly CEA4,5 recommended it as a treatment for symptomatic
patients with severe carotid artery stenosis.However, only few
studies suggest that plaque vulnerability and oxidized stress
are higher in the acute than in the late stage. According to
Redgrave et al,21 plaques removed earlier than 60 days after
the most recent stroke were more unstable than those re-
moved at more than 180 days after last recent stroke, thus
suggesting that vulnerable plaques in the acute phase may
become stable. Our finding that the incidence of vulnerable
plaques was higher in group A than in group B may support
this hypothesis.
Rothwell et al5 reported that with respect to treatment
outcome, there was a sex difference in the effect of time
from symptom onset to CEA; the benefits derived by
women decreased rapidly in the first few weeks, whereas
men benefited even from delayed CEA.5 They postulated
that plaque in women was more frequently attributable to
endothelial erosion than to plaque rupture. We cannot
comment on this point because too few (n 11; 15.3%) of
our 72 patients were women, and 57.8% of all group B
patients manifested vulnerable plaques.
The importance of oxidized LDL in the pathogenesis of
roup A; B, group B). *P  .05. B, Plaque oxidized
1.C, Plaquematrix metalloproteinase (MMP)-9 activity
. *P  .05. E, Plaque zymography in each group. The
ple. MMP-9 was strongly positive in groups Av and Bv.(A, g
 .0
roup
e samatherosclerosis has been documented.8,9 Oxidized LDL ex-
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vivo, including inducing foam cell formation from macro-
phages. In our previous studies, we determined plasma and
plaque oxidized LDL levels by sandwich enzyme-linked im-
munosorbent assay by usingDLH3and anti-apolipoproteinB
antibodies and explored their correlation with carotid athero-
sclerosis.11 We found that in patients with vulnerable plaque
that was harvestedmore than 4weeks after the last symptoms,
the oxidized LDL levels were significantly higher than in the
controls and patients with stable plaques, thus suggesting that
plaque oxidized LDL is associated with plaque instability.11
There was a strong correlation between plaque oxidized LDL
levels and plaque instability. Our current findings confirm our
Fig 4. Matrix metalloproteinase (MMP)-9 and oxidiz
plaques in groups Av and Bv. In sequential specimens
antigen was performed at least two times.
D
A
Group As
Group Bs
Fig 5. Matrix metalloproteinase (MMP)-9 and oxidized
in groups As and Bs. In sequential specimens from each
performed at least two times.earlier observations that higher oxidized LDL levels werecorrelated with plaque vulnerability in both the acute and late
stages. Furthermore, in vulnerable plaques, high oxidized
LDL expression was correlated with high MMP-9 activity.
Macrophages in human atherosclerotic plaques produce a
family of MMP that may affect vascular remodeling and
plaque disruption.22 Because oxidized LDL upregulates
MMP-9 expression,23 it may contribute to a macrophage-
mediatedmatrix breakdown in atherosclerotic plaques. In our
series, the plaque MMP-9 activity did not differ significantly
between group A and group B, but it was higher in vulnerable
than in stable plaques. We previously demonstrated that an
imbalance in the oxidant/antioxidant system correlated with
plaque vulnerability.12 The manganese superoxide dismutase
w-density lipoprotein (OxLDL) staining of vulnerable
each plaque sample, the immunostaining against each
F
MP-9 OxLDL
C
Bar = 500 µm
-density lipoprotein (OxLDL) staining of stable plaques
e sample, the immunostaining against each antigen wased lo
fromE
M
B
low
plaqugene is upregulated in response to oxidative stress, and, in fact,
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crease inMnSOD. Thus, the antioxidant systemmay contrib-
ute to the stabilization of vulnerable plaques, and in some
cases, an ischemic episode may be followed by plaque healing
and a relatively quiescent state in the late phase. Conversely,
57.8% of our symptomatic patients were exposed to high
oxidant stress even in the late phase, thus suggesting that the
persistent increase of oxidized LDL may lead to MMP-9
upregulation, rendering the plaque vulnerable during the late
phase, and that this may lead to the induction of further
ischemic attacks. Although we did not assess the balance of
matrix degradation enzymes and their inhibitors in this study,
a reduction in MMP-9 inhibitors such as tissue inhibitor of
metalloproteinases 1 and 2 may be associated with plaque
vulnerability.23
In conclusion, here we first demonstrated that vulner-
able plaques in patients subjected to early CEA manifested
a remarkable increase in oxidized LDL and MMP-9 activa-
tion. Our findings suggest that early CEAmay be beneficial
in the aspect of oxidative stress.
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